HemaSphere
(Aug 2023)
P969: VRD OUTPERFORMED VCD AS INDUCTION THERAPY BEFORE FIRST-LINE ASCT IN MULITPLE MYELOMA; RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY
- Jakob Nordberg Nørgaard,
- Kari Lenita Falck Moore,
- Tobias Slørdahl,
- Anders Vik,
- Tor Henrik Anderson Tvedt,
- Fredrik Schjesvold
Affiliations
- Jakob Nordberg Nørgaard
- 1 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
- Kari Lenita Falck Moore
- 1 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
- Tobias Slørdahl
- 4 Department of Hematology, St. Olavs Hospital, Trondheim, Norway
- Anders Vik
- 6 Department of Hematology, University Hospital of North Norway, Tromsø, Norway
- Tor Henrik Anderson Tvedt
- 8 Department of Hematology, Oslo University Hospital, Oslo, Norway
- Fredrik Schjesvold
- 1 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
- DOI
-
https://doi.org/10.1097/01.HS9.0000970780.55147.2c
- Journal volume & issue
-
Vol. 7
p.
e551472c
WeChat QR code